Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397543 | 1.00 | NT5E (0.54) | NT5EPABPC1HDAC4PTGESKDM4E | |
| SCHEMBL30134165 | 0.93 | NT5E (0.54) | NT5EPABPC1HDAC4PTGESKDM4E | |
| SCHEMBL20364201 | 0.93 | NT5E (0.54) | NT5EPABPC1HDAC4PTGESKDM4E | |
| SCHEMBL13208485 | 0.82 | PABPC1 (0.41) | NT5EPABPC1PTGESHTTCYP1A2 | |
| SCHEMBL30134297 | 0.79 | NT5E (0.44) | NT5EPABPC1HDAC4PTGESHTT | |
| SCHEMBL14242807 | 0.79 | ESR2 (0.42) | NT5EHDAC4KDM4EHTTMAPT | |
| SCHEMBL20364204 | 0.79 | TLR9 (0.50) | NT5EHDAC4KDM4EHTTPIK3CA | |
| SCHEMBL13347723 | 0.79 | NQO2 (0.46) | HDAC4KDM4EHTTCYP1A2LMNA | |
| SCHEMBL30702108 | 0.79 | TLR9 (0.50) | NT5EHDAC4KDM4EHTTPIK3CA | |
| Hydrochloric Acid SCHEMBL28217861 | 0.77 | TLR9 (0.49) | NT5EHDAC4KDM4EHTTPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| WO-2024160277-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
| US-20170305900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9617259-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160031876-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-02-04 | — | — | US | disclosed |
| EP-2968207-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI Foundation, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014159218-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS | CHDI FOUNDATION, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | NT5E 1696/4885PABPC1 4695/4885HDAC4 132/4885 |
| US-20160031876-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | NT5E 3216/4885PABPC1 2559/4885HDAC4 10/4885 |
| US-20170305900-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | NT5E 3216/4885PABPC1 2559/4885HDAC4 10/4885 |
| US-10421742-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | NT5E 499/4885PABPC1 2032/4885HDAC4 4036/4885 |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NT5E 499/4885PABPC1 2032/4885HDAC4 4036/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | NT5E 2203/4885PABPC1 2273/4885HDAC4 400/4885 |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NT5E 499/4885PABPC1 2032/4885HDAC4 4036/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | NT5E 2467/4885PABPC1 1281/4885HDAC4 691/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | NT5E 2467/4885PABPC1 1281/4885HDAC4 691/4885 |
| US-10106535-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC5 | NT5E 3216/4885PABPC1 2559/4885HDAC4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.